N/A N=50 Postpartum Continuous Glucose Monitoring (CGM) Study
Gestational Diabetes
Primary: Number of Participants With at Least 72 Hours of CGM Data Downloaded. — 43 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 Live Video Mind-body Treatment to Prevent Persistent Symptoms Following mTBI
MTBI - Mild Traumatic Brain Injury · Anxiety
Primary: Number of Participants Who Scored Above the Midpoint on Each Subscale of the Credibility and Expectancy Questionnaire (CEQ) — 21; 23; 16; 19 Participants
Phase 3 N=3,533 A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
Diabetes Mellitus, Type 2
Primary: Number of Participants From Time of Randomization to First Occurrence of Onset of Persistent ≥50% Reduction in eGFR(CKD-EPI); Onset of Persistent eGFR(CKD-EPI)…
Phase 1 N=20 A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms
Healthy
Primary: Maximum Change From Baseline in Panic Symptom Scale (PSS) Sum Intensity Score — 22.639; 29.944 Score on a scale
N/A N=97 Multicenter Trial for the Validation of Vitalera Platform
Chronic Patients · Heart Failure
Primary: Change in Quality of Life Scale Between Baseline and 3-months Follow-up — -24; -32.5 units on a scale — p=0.252
N/A N=19 Tissue Optimization on Cryolipolysis Procedures for Fat Layer Reduction
Body Fat Disorder
Primary: Percentage of Before and After Side-by-side Photographs Correctly Identified by At Least 2 of 3 Blinded Reviewers From the Independent Physician Reviewer (IPR) Panel…
Phase 2 N=18 A Study of JR-171 in Patients With Mucopolysaccharidosis I
Mucopolysaccharidosis I
Primary: Number of Participants With Adverse Events — 3; 6; 7; 0 participants
Phase 2 N=50 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Uterine Corpus Carcinoma · Stage III Uterine Corpus Cancer AJCC v7
Primary: Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)). — 68…
N/A N=278 Evaluation of the Efficacy and Mechanisms of a Novel Intervention for Chronic Pain Tailored to People Living With HIV
Chronic Pain
Primary: Brief Pain Inventory (BPI) Total Score — 4.74; 5.99; 5.13; 5.74 score on a scale
N/A N=37 Effects of Exercise on Glymphatic Functioning and Neurobehavioral Correlates in Parkinson's Disease
Parkinson's Disease and Parkinsonism · Glymphatic System
Primary: Change in Beta-Amyloid Levels — 0.016675963 SUVr
Phase 2 N=55 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies
AML · CMML · MDS
Primary: Safety Assessed by Adverse Events — 3; 3; 4; 4 participants
Phase 3 N=86 A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab
Atopic Dermatitis
Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI-75) at Week 16 — 57.4 percentage of participants
Phase 3 N=708 Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I
Glabellar Frown Lines
Primary: Facial Wrinkle Scale (FWS) Score of 0 or 1 and an Improvement of ≥ 2 Points in FWS Score (at Maximum Frown) at Week 4 Visit Relative to Baseline, Based on Both the…
Phase 3 N=327 The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Dry Eye · Dry Eye Syndromes
Primary: Conjunctival Redness Assessed Over 90 Minutes in the Dry Eye Chamber — 0.185; 0.156 units on a scale
N/A N=492 Second eFramngham Heart Study
Cardiovascular Diseases
Primary: Proportion of Surveys/Tasks Returned in Period 1 — 0.85; 0.85 proportion of surveys returned